Journal
CELL
Volume 182, Issue 6, Pages 1401-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2020.08.002
Keywords
-
Categories
Funding
- Ligue Nationale Contre le Cancer (Equipes labellisees)
- Agence Nationale de la Recherche (IHU PRISM)
- Institut National du Cancer (SIRIC CARPEM)
- Fondation ARC
- Fondation pour la Recherche Medicale
- Singapore Immunology Network (SIgN) core funding
- Singapore National Research Foundation Senior Investigatorship (NRFI) [NRF2016NRF-NRFI001-02]
- SIgN core funding
- Institut National du Cancer (SOCRATE)
Ask authors/readers for more resources
Blood myeloid cells are known to be dysregulated in coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2. It is unknown whether the innate myeloid response differs with disease severity and whether markers of innate immunity discriminate high-risk patients. Thus, we performed high-dimensional flow cytometry and single-cell RNA sequencing of COVID-19 patient peripheral blood cells and detected disappearance of non-classical CD14(Low)CD16(High) monocytes, accumulation of HLA-DRLow classical monocytes (Human Leukocyte Antigen - DR isotype), and release of massive amounts of calprotectin (S100A8/S100A9) in severe cases. Immature CD10(Low)CD101(-)CXCR4(+/-) neutrophils with an immunosuppressive profile accumulated in the blood and lungs, suggesting emergency myelopoiesis. Finally, we show that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe form of COVID-19, suggesting a predictive value that deserves prospective evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available